ArticleMolecular pharmaceutics2010
Thermoresponsive hydrogel as a delivery scaffold for transfected rat mesenchymal stem cells.
Article in Molecular pharmaceutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bioengineering Strategies for Corneal Endothelial Cell Injection Therapy: Advances, Challenges, and Clinical Translation.Bioengineering (Basel, Switzerland) · 2025Review
- Boosting therapeutic efficacy of mesenchymal stem cells in pulmonary fibrosis: The role of genetic modification and preconditioning strategies.Iranian journal of basic medical sciences · 2023Review
- An Overview on Thermosensitive Oral Gel Based on Poloxamer 407.Materials (Basel, Switzerland) · 2021Review
- Bioreducible polymers for therapeutic gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Thermally reversible colloidal gels for three-dimensional chondrocyte culture.Journal of the Royal Society, Interface · 2012Article
- Matrix metalloproteinase-sensitive thermogelling polymer for bioresponsive local drug delivery.Acta biomaterialia · 2011Article
- Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The concept of stem cells as a therapeutic agent has been gaining momentum. A common mode of administration of these cells is by direct injection into the target tissue. This can result in many of the cells being lost due to reflux from the injection site leading to a local loss of implanted cells. PoligoGel is a nontoxic hydrogel with an LCST near body temperature. It is also shown to be nontoxic to multiple cell types, and in the case of rat mesenchymal stem cells does not alter their differentiative capacity, either by inducing differentiation, or limiting the potential for subsequent differentiation after removal from the gel. Embedding cells in PoligoGel also does not interfere with the cells' ability to delivery therapeutic growth factors post transfection with plasmid DNA. Here a thermoresponsive hydrogel, PoligoGel, is shown to have potential to act as a scaffold for the retention of cells at an injection site, mitigating migration or washing of the cells away from the target site after implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.